Response Biomedical (V.RBM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Response Biomedical (V.RBM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Starowl who wrote (342)	11/4/2000 1:13:10 PM
From: Rob	Read Replies (1) of 655

Its not the fund as one can tell from the pattern and from the brokerage house. 1/2 hour before close one "investor" started dumping through Canaccord. Management figured out who it was and apparently had a positive discussion and expect a recovery Monday. It will be interesting as there will be some confident investors who perhaps try to quickly pickup some cheap shares and perhaps others that react on emotion. You'd have to ask this "investor" yourself why he chose to sell (tax losses, divorce, loss of senses ???). Regardless, a dumb way to do it. He likely could have received a higher price by contacting the company to arrange a cross corresponding with the next financing. Instead, he's freaked out other investors and provided quite a bargain to a number of others who quickly picked them up. I don't agree with your assumption that its one person buying (only slightly more than 1/2 were bought through Canaccord which quite a number of Response shareholders use). There are quite a few investors who are willing to pickup cheap shares and keep low bids in. Perhaps, some insiders also decided this was too good to pass up. One can pickup an easy and quick 50% to 100% gain from these levels in a couple months as the company is only months from hitting some major milestones. To recap, recent positives include: - development deal with ischemia who has the top two POC experts on their SAB, one of who is on Biosite's. Within weeks of Response announcing they have a deal with Ischemia for an ischemia test based on an already developed and patented marker, Biosite announced that it was undergoing a program to develop an ischemia marker. - Addition of full-time highly qualified CEO and President - one already familiar with the product and the potential - Addition of an experienced CFO - excellent independent pre-clinical test results through UBC - excellent independent test results conducted by IRC - chinese distribution deal with the largest distributor of NA medical devices in China. - contract to do feasibility on digoxin through Battelle who apparently represented one of the top NA pharmas and with whom partnerhsip discussion are rumoured to be underway. An analyst recently showed statistics that, on average, 80% of stock gains are made between Nov and April.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next